SCHEMBL4279263

SCHEMBL4279263

CCOC(=O)n1nc(NC(=O)c2ccc(N3CCN(C)CC3)c(N(C)CCOC)c2)c2c1CN(S(=O)(=O)c1cccc(F)c1)C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.39
USP2 O75604 5/20 0.38
HSD17B10 Q99714 2/20 0.38
TP53 P04637 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
ALDH1A1 P00352 5/20 0.38
KMT2A Q03164 5/20 0.38
GAA P10253 4/20 0.38
MEN1 O00255 4/20 0.38
HPGD P15428 3/20 0.38
MAPT P10636 3/20 0.38
NPSR1 Q6W5P4 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ESR1 P03372 1/20 0.36
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4279221 0.88 IGF1R (0.42) IGF1RUSP2HSD17B10TP53CYP1A2
SCHEMBL4287268 0.86 TAAR1 (0.42) IGF1RUSP2HSD17B10TP53CYP1A2
SCHEMBL4283502 0.86 MAPT (0.46) IGF1RUSP2HSD17B10TP53CYP1A2
SCHEMBL13857402 0.85 USP2 (0.35) USP2HSD17B10TP53CYP1A2CYP3A4
SCHEMBL4278036 0.82 MAPK14 (0.35) CYP2C19ALDH1A1KMT2AMEN1MAPT
SCHEMBL4293087 0.81 FGFR1 (0.35) HSD17B10MAPTNPSR1SMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL4293085 0.80 FGFR1 (0.34) HSD17B10MAPTNPSR1SMN1; SMN2LMNA
SCHEMBL4281350 0.78 IGF1R (0.55) IGF1R
SCHEMBL4282875 0.78 IGF1R (0.45) IGF1RUSP2ALDH1A1KMT2AGAA
SCHEMBL1889132 0.75 IGF1R (0.47) IGF1RUSP2ALDH1A1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
EP-1999131-B1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-10-23 EP disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS MAP3K19, CDK2, MAP3K1 IGF1R 530/4885USP2 3984/4885HSD17B10 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.